• Adaptive Biotechnologies reported an EPS of -$0.23, surpassing the estimated -$0.27, marking an improvement from the previous year.
• The company's revenue was approximately $47.5 million, exceeding the estimated $46 million and showing growth from the previous year.
• ADPT has a strong liquidity position with a current ratio of 3.52, but faces profitability challenges with a negative earnings yield and P/E ratio.

Adaptive Biotechnologies (NASDAQ:ADPT) is a company in the biomedical and genetics industry, focusing on immune-driven medicine to transform the diagnosis and treatment of disease. ADPT competes with other companies in the medical and biotechnology sectors. On February 11, 2025, ADPT reported its earnings, showing an EPS of -$0.23, which was better than the estimated -$0.27.

The company's EPS performance marks an improvement from the previous year's loss of $0.30 per share. This resulted in an earnings surprise of 11.54%, as highlighted by Zacks. In the previous quarter, ADPT was expected to post a loss of $0.30 per share but reported a loss of $0.22, delivering a surprise of 26.67%. Over the past four quarters, ADPT has consistently surpassed consensus EPS estimates.

ADPT reported revenue of approximately $47.5 million, surpassing the estimated $46 million. This revenue exceeded the Zacks Consensus Estimate by 2.23%. Compared to the $45.78 million reported in the same quarter the previous year, this shows growth. ADPT has outperformed consensus revenue estimates three times in the last four quarters.

The company has a price-to-sales ratio of about 6.49, indicating how the market values its sales. Its enterprise value to sales ratio is around 6.80, reflecting its total valuation in relation to sales. ADPT's debt-to-equity ratio is 0.41, suggesting a moderate level of debt compared to equity.

ADPT's current ratio of 3.52 implies a strong liquidity position, with more than three times the current assets compared to current liabilities. However, the company faces financial challenges with a negative earnings yield and a negative price-to-earnings ratio, indicating issues with profitability.